Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic

About this episode

The episode discusses the evolving management of ESR1-mutated metastatic breast cancer and the complexities in treatment decisions.

As the management of patients with ESR1-mutated metastatic breast cancer evolves,various questions have emerged in clinical practice. “It's a complex situation,” explainsHope S. Rugo, MD, division chief of breast medical oncology and the Women's CancersProgram director at the City of Hope Comprehensive Cancer Center in Duarte,California. She discusses how recent advances have changed treatment decisions withRobert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology atCedars-Sinai Cancer in Los Angeles. “I think it's important to keep in mind that today wejust have single-agent oral SERDs, and people like to give combinations,” Dr. Rugonotes. But what combinations to give and when remains unclear. “I think how we'regoing to decide is that we're going to wait and see what's approved and then look atpatients to try and figure out what to do,” she offers.

People in this episode

Guests: Hope S. Rugo, Robert A. Figlin

Topics covered

• ESR1-mutated breast cancer
• treatment decisions
• clinical practice
• oral SERDs
• combination therapy

Keywords

• ESR1 mutation
• breast cancer
• treatment advances
• clinical decisions
• SERDs
• oncology

Mentioned in this episode

Organizations: City of Hope Comprehensive Cancer Center, Cedars-Sinai Cancer

Places: Duarte, California, Los Angeles

More episodes of Oncology News Central Peer-Spectives

• “Not a Straightforward Decision”: What to Do While Waiting on a Practice Change in Breast Cancer Care · April 29, 2026 · 11 min
• New Targeted Therapies Make Breast Cancer Treatment Decisions “a Bit of a Moving Target” · April 21, 2026 · 9 min
• Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care · April 2, 2026 · 14 min
• Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC · December 18, 2025 · 12 min
• “Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions · December 18, 2025 · 15 min
• “Is the Juice Worth the Squeeze?”: Treatment Intensification for Advanced EGFRm NSCLC · December 16, 2025 · 13 min